Table 1.

Multivariate analysis of disease-free survival in patients with stage II and III colorectal cancer from the clinical cohort

Stage II + IIIUnivariateMultivariate
CovariateHR (95% CI)PHR (95% CI)P
*Age (>median (66) vs. <median)1.02 (0.65–1.61)0.93
Gender (male vs. female)1.02 (0.64–1.62)0.94
*Tumor size (>45 mm vs. <45 mm)1.08 (0.66–1.76)0.76
Vascular invasion (positive vs. negative)1.29 (0.74–2.49)0.47
Mucinous (positive vs. negative)1.36 (0.64–2.62)0.32
Perineural invasion (positive vs. negative)1.87 (1.01–3.45)0.0461.73 (0.89–3.34)0.11
Lymph node (positive vs. negative)1.89 (1.14–3.12)0.0142.17 (1.06–4.46)0.034
TFAP2E methylation (high vs. low)1.81 (1.10–2.98)0.0191.91 (1.02–3.58)0.045
Stage II
Covariate
*Age (>median (66) vs. <median)0.66 (0.27–1.63)0.37
Gender (male vs. female)0.76 (0.32–1.78)0.53
*Tumor size (>45 mm vs. <45 mm)0.89 (0.35–2.25)0.79
Mucinous (positive vs. negative)0.8 (0.18–3.47)0.77
Perineural invasion (positive vs. negative)1.5 (0.46–4.86)0.49
Vascular invasion (positive vs. negative)2.17 (0.67–7.05)0.22.11 (0.59–7.51)0.25
TFAP2E methylation (high vs. low)3.14 (1.09–9.01)0.0351.91 (1.20–25.95)0.029
  • Abbreviations: CI, confidence interval; *, median values used. TFAP2E methylation (high >40%; low ≤40%).